Amgen, Hypermarcas deal

Hypermarcas will return Brazilian rights to Amgen for colorectal cancer drug Vectibix panitumumab and for hyperparathyroidism and hypercalcemia drug Mimpara cinacalcet, which are approved in Brazil, and idiopathic thrombocytopenic purpura (ITP) candidate romiplostim, which is under review in Brazil. Hypermarcas said it will receive between BRL30-BRL35 million ($17.9-$20.9 million). Hypermarcas gained rights to the products with its 2010 acquisition of Mantecorp Industria Quimica e Farmacêutica S.A. ...